Peroxisome proliferator-activated receptors: Bridging metabolic syndrome with molecular nutrition

Clinical Nutrition

Volumn 25, Issue 6, 2006, Pages 871-885

  Guri, Amir J ^a   Hontecillas, Raquel ^a   Bassaganya Riera, Josep ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Adipocyte hypertrophy; Inflammation; Metabolic syndrome; Obesity; PPAR

Indexed keywords

ABSCISIC ACID; ADIPOCYTOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CONJUGATED LINOLEIC ACID; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOL DERIVATIVE; UNCLASSIFIED DRUG;

ADIPOCYTE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL STRUCTURE; COLITIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; FAT INTAKE; FATTY ACID OXIDATION; FOOD COMPOSITION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE OXIDATION; HUMAN; HYPERTROPHY; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LIGAND BINDING; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIVER METABOLISM; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SKELETAL MUSCLE; STROMA CELL; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ANIMALS; CELL DIVISION; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; NUTRITION PHYSIOLOGY; OBESITY; ORGAN SPECIFICITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 33751006412     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2006.08.006     Document Type: Review

References (117)

1. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood) Suppl. Web Exclusives 2003; W3-219-226.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
3. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the american diabetes association and the european association for the study of diabetes. Diabetes Care 28 (2005) 2289-2304
4. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
5. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
6. CDC: National diabetes fact sheet: general information and national estimates on diabetes in the United States. US Department of Health and Human Services, Center for Disease Control and Prevention, Atlanta, Georgia, 2005. p. 1-10.
7. Zempleni J. Molecular nutrition (2003), CABI Publishing, Lincoln, Nebraska
8. Kovacs P., and Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19 (2005) 625-635
9. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
10. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94 (1997) 4318-4323
11. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
12. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
13. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 115 (2005) 1111-1119
14. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
15. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
16. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
17. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98 (2001) 2005-2010
18. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
19. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
20. Bruun J.M., Pedersen S.B., and Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res 32 (2000) 537-541
21. Bouloumie A., Curat C.A., Sengenes C., Lolmede K., Miranville A., and Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8 (2005) 347-354
22. Robker R.L., Collins R.G., Beaudet A.L., Mersmann H.J., and Smith C.W. Leukocyte migration in adipose tissue of mice null for ICAM-1 and Mac-1 adhesion receptors. Obes Res 12 (2004) 936-940
23. Cinti S., Mitchell G., Barbatelli G., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46 (2005) 2347-2355
24. Ozcan U., Cao Q., Yilmaz E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
25. Gao Z., Hwang D., Bataille F., et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 277 (2002) 48115-48121
26. Hotamisligil G.S. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 Suppl. 3 (2003) S53-S55
27. Hirosumi J., Tuncman G., Chang L., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
28. Yuan M., Konstantopoulos N., Lee J., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (2001) 1673-1677
29. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
30. Curat C.A., Wegner V., Sengenes C., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49 (2006) 744-747
31. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 (2003) 1821-1830
32. Weisberg S.P., Hunter D., Huber R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116 (2006) 115-124
33. Kadowaki T., Hara K., Yamauchi T., Terauchi Y., Tobe K., and Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228 (2003) 1111-1117
34. Kruszynska Y.T., Mukherjee R., Jow L., Dana S., Paterniti J.R., and Olefsky J.M. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 101 (1998) 543-548
35. Selvaraj R.K., and Klasing K.C. Lutein and eicosapentaenoic acid interact to modify iNOS mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines. J Nutr 136 (2006) 1610-1616
36. Epple R., Azimioara M., Russo R., et al. 1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists. Bioorg Med Chem Lett 16 (2006) 2969-2973
37. Willson T.M., and Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1 (1997) 235-241
38. Banner C.D., Gottlicher M., Widmark E., Sjovall J., Rafter J.J., and Gustafsson J.A. A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma. J Lipid Res 34 (1993) 1583-1591
39. Hostetler H.A., Kier A.B., and Schroeder F. Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARalpha). Biochemistry 45 (2006) 7669-7681
40. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997) 4312-4317
41. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
42. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARgamma. Cell 83 (1995) 803-812
43. Chawla A., Lee C.H., Barak Y., et al. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100 (2003) 1268-1273
44. Guri A, Hontecillas R, Si H, Lui D, Bassaganya-Riera J. Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high fat diets. Clin Nutr 2006; in press, doi:10.1016/j.clnu.2006.07.008.
45. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem 270 (1995) 12953-12956
46. Ren D., Collingwood T.N., Rebar E.J., Wolffe A.P., and Camp H.S. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16 (2002) 27-32
47. Otto T.C., and Lane M.D. Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol 40 (2005) 229-242
48. Bassaganya-Riera J., Guri A., King J., and Hontecillas R. Peroxisome proliferator-activated receptors: the nutritionally controlled molecular networks that integrate inflammation, immunity and metabolism. Curr Nutr Food Sci 1 (2005) 179-187
49. Wilson-Fritch L., Nicoloro S., Chouinard M., et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114 (2004) 1281-1289
50. Jones J.R., Barrick C., Kim K.A., et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 102 (2005) 6207-6212
51. Reed B.C., and Lane M.D. Insulin receptor synthesis and turnover in differentiating 3T3-L1 preadipocytes. Proc Natl Acad Sci USA 77 (1980) 285-289
52. Tsuchida A., Yamauchi T., Takekawa S., et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54 (2005) 3358-3370
53. Wang Y.X., Lee C.H., Tiep S., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
54. Hammarstedt A., Andersson C.X., Rotter Sopasakis V., and Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 65-75
55. Holevinsky K.O., and Nelson D.J. Simultaneous detection of free radical release and membrane current during phagocytosis. J Biol Chem 270 (1995) 8328-8336
56. Cancello R., Henegar C., Viguerie N., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54 (2005) 2277-2286
57. Guida E., and Stewart A. Influence of hypoxia and glucose deprivation on tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor expression in human cultured monocytes. Cell Physiol Biochem 8 (1998) 75-88
58. Castrillo A., and Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20 (2004) 455-480
59. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
60. Kelly D., Campbell J.I., King T.P., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5 (2004) 104-112
61. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 100 (2003) 6712-6717
62. Lee J.Y., and Hwang D.H. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Mol Cells 21 (2006) 174-185
63. Lee J.Y., Zhao L., Youn H.S., et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 279 (2004) 16971-16979
64. Eun C.S., Han D.S., Lee S.H., et al. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci 51 (2006) 693-697
65. Lefebvre P., Chinetti G., Fruchart J.C., and Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116 (2006) 571-580
66. Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536 (2006) 182-191
67. Oh K.S., Kim M., Lee J., et al. Liver PPARalpha and UCP2 are involved in the regulation of obesity and lipid metabolism by swim training in genetically obese db/db mice. Biochem Biophys Res Commun 345 (2006) 1232-1239
68. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31 (2003) 1066-1069
69. Caslake M.J., Packard C.J., Gaw A., et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 13 (1993) 702-711
70. Patsouris D., Mandard S., Voshol P.J., et al. PPARalpha governs glycerol metabolism. J Clin Invest 114 (2004) 94-103
71. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103 (1999) 1489-1498
72. Ravnskjaer K., Boergesen M., Rubi B., et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells. Endocrinology 146 (2005) 3266-3276
73. Tontonoz P., Hu E., Devine J., Beale E.G., and Spiegelman B.M. PPARgamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15 (1995) 351-357
74. Devine J.H., Eubank D.W., Clouthier D.E., et al. Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo. J Biol Chem 274 (1999) 13604-13612
75. Holness M.J., Bulmer K., Smith N.D., and Sugden M.C. Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone. Biochem J 369 (2003) 687-695
76. Tanaka T., Masuzaki H., Ebihara K., et al. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice. Metabolism 54 (2005) 1490-1498
77. Walczak R., and Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 43 (2002) 177-186
78. Janssen I., Heymsfield S.B., Wang Z.M., and Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 89 (2000) 81-88
79. Barish G.D., Narkar V.A., and Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116 (2006) 590-597
80. Norris A.W., Chen L., Fisher S.J., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112 (2003) 608-618
81. Vidal-Puig A.J., Considine R.V., Jimenez-Linan M., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99 (1997) 2416-2422
82. De Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG. Agonists of the peroxisome proliferator activated receptor alpha (PPAR{alpha}) induce a fiber-type selective transcriptional response in rat skeletal muscle. Toxicol Sci 2006.
83. Abbot E.L., McCormack J.G., Reynet C., Hassall D.G., Buchan K.W., and Yeaman S.J. Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J 272 (2005) 3004-3014
84. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2 (2001) 282-286
85. Wang Y., Jones Voy B., Urs S., et al. The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J Nutr 134 (2004) 1032-1038
86. He J., Watkins S., and Kelley D.E. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50 (2001) 817-823
87. Dressel U., Allen T.L., Pippal J.B., Rohde P.R., Lau P., and Muscat G.E. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17 (2003) 2477-2493
88. Luquet S., Lopez-Soriano J., Holst D., et al. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 86 (2004) 833-837
89. Finck B.N., Han X., Courtois M., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100 (2003) 1226-1231
90. van Loon L.J., and Goodpaster B.H. Increased intramuscular lipid storage in the insulin-resistant and endurance-trained state. Pflugers Arch 451 (2006) 606-616
91. Goodpaster B.H., Thaete F.L., and Kelley D.E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 71 (2000) 885-892
92. Gallagher D., Kuznia P., Heshka S., et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr 81 (2005) 903-910
93. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., and Kern P.A. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97 (1996) 1111-1116
94. Stein D.T., Stevenson B.E., Chester M.W., et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 100 (1997) 398-403
95. Tordjman K., Standley K.N., Bernal-Mizrachi C., et al. PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. J Lipid Res 43 (2002) 936-943
96. Koshkin V., Wang X., Scherer P.E., Chan C.B., and Wheeler M.B. Mitochondrial functional state in clonal pancreatic beta-cells exposed to free fatty acids. J Biol Chem 278 (2003) 19709-19715
97. Parton L.E., Diraison F., Neill S.E., et al. Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays. Am J Physiol Endocrinol Metab 287 (2004) E390-E404
98. Yajima K., Hirose H., Fujita H., et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 284 (2003) E966-E971
99. Imbeault P., Lemieux S., Prud'homme D., et al. Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous fat cell hypertrophy?. Metabolism 048 (1999) 355-362
100. George J., Afek A., Shaish A., et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104 (2001) 1646-1650
101. Hiramatsu K., Rosen H., Heinecke J.W., Wolfbauer G., and Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis 7 (1987) 55-60
102. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
103. Guo J., Van Eck M., de Waard V., et al. The presence of leukocyte CC-chemokine receptor 2 in CCR2 knockout mice promotes atherogenesis. Biochim Biophys Acta 1740 (2005) 453-459
104. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
105. Febbraio M., Abumrad N.A., Hajjar D.P., et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 274 (1999) 19055-19062
106. Chawla A., Boisvert W.A., Lee C.H., et al. A PPARgamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001) 161-171
107. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
108. Oliver Jr. W.R., Shenk J.L., Snaith M.R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98 (2001) 5306-5311
109. Vosper H., Patel L., Graham T.L., et al. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276 (2001) 44258-44265
110. Li A.C., Binder C.J., Gutierrez A., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114 (2004) 1564-1576
111. Verrier E., Wang L., Wadham C., et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 94 (2004) 1515-1522
112. Dragomir E., Tircol M., Manduteanu I., Voinea M., and Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vasc Pharmacol 44 (2006) 440-449
113. Mishra A., Chaudhary A., and Sethi S. Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol 24 (2004) 1621-1627
114. Roberts CK, Won D, Pruthi S, et al. Effect of a diet and exercise intervention on oxidative stress, inflammation, MMP-9 and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2005.
115. Ajuwon K.M., and Spurlock M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288 (2005) R1220-R1225
116. Tanaka T., Fukunaga Y., Itoh H., et al. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 508 (2005) 255-265
117. Babaev V.R., Yancey P.G., Ryzhov S.V., et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25 (2005) 1647-1653